Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AFFYMETRIX (AFFX) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (1584)	12/18/2002 4:13:12 PM
From: tuck	Read Replies (1) \| Respond to of 1728

>>MOUNTAIN VIEW, Calif., Dec. 18 /PRNewswire/ -- Perlegen Sciences, Inc., a privately-held genetics company, announced today that it has entered into a research collaboration with Eli Lilly and Company (NYSE: LLY - News). Perlegen will use its proprietary high-resolution whole genome association technologies and over 1.5 million Perlegen-identified single nucleotide polymorphisms (SNPs) to identify genetic markers for Lilly. Lilly will provide Perlegen with undisclosed research funding and potential milestone payments and royalties. Perlegen will also obtain certain rights to develop products including novel therapeutics based on the research results. As part of the research collaboration, Lilly will make an equity investment in Perlegen. "We look forward to using Perlegen's technologies to accelerate the development of important therapeutics and diagnostics for Lilly through high-resolution whole genome scanning," said Brad Margus, CEO of Perlegen. "This kind of research will apply Perlegen's capabilities to improving the lives of patients."<< snip Cheers, Tuck